SAN DIEGO, Calif., Feb. 8 /PRNewswire/ -- NexBio, Inc. today announced the issuance by the United States Patent and Trademark Office of United States Patent No. 7,645,448 entitled “Class of Therapeutic Protein Based Molecules”. This patent covers NexBio’s sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase((R))), and methods of treating or preventing viral infection by influenza and parainfluenza with such compositions.
“This patent further validates the unique and pioneering nature of the host-targeting approach used by DAS181 for the potential therapy and prophylaxis of any and all strains of influenza and parainfluenza virus,” said David Wurtman, MD, MBA, VP of Corporate Development of NexBio. “Our data show that by acting on sialic acid, the human receptor for these viruses, DAS181 appears to decrease the probability of drug resistance developing, while also offering an approach that may work when resistance has developed to other antivirals such as Tamiflu((R)), Relenza((R)) and peramivir,” Dr. Wurtman added.
ABOUT NEXBIO
For more information about NexBio, Inc., please visit http://www.nexbio.com
DISCLOSURE NOTICE:
CONTACT: David Wurtman, M.D., M.B.A., VP, Corporate Development of NexBio,
Inc., +1-858-452-2631, dwurtman@nexbio.com
Web site: http://www.nexbio.com/
